Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pathologic Misclassification of Renal Cell Carcinoma in Adolescents and Young Adults.

Cancers·2026
Same author

Indocyanine Green Fluorescence for Intraoperative Tumor Identification During Resection of Pediatric and Adolescent Intra-Abdominal Malignancy: A Prospective Multi-Institutional Observational Study.

Journal of the American College of Surgeons·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Oncologic outcomes of parenchyma-sparing resection for hepatoblastoma.

Journal of pediatric surgery·2026
Same author

Survivorship After Testicular Cancer in Adolescents and Young Adults: What is Causing Death and When?

The Journal of urology·2026
Same author

Incidence, predictive factors, and proposed classification of wound complications in pediatric extremity bone sarcoma patients following extirpative surgery.

Journal of pediatric surgery·2026

相关实验视频

Updated: May 5, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.1K

拉布多米索尔科马手术更新

Timothy Rogers1, Andreas Schmidt2, Amanda F Buchanan3

  • 1Department of Paediatric Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Pediatric blood & cancer
|January 14, 2025
PubMed
概括

随着手术切除和化疗的进步,肌肉肉瘤 (RMS) 治疗得到了改善. 新的分期技术和风险分层正在改进儿科癌症治疗,尽管国际标准化工作仍在继续.

关键词:
当地的控制控制.辐射证据水平:IV 证据水平:IV拉布多米索科马 (rhabdomyosarcoma) 是一种肌肉癌.手术 手术 手术 手术 手术 手术 手术

更多相关视频

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.5K

相关实验视频

Last Updated: May 5, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.5K

科学领域:

  • 儿科瘤学 儿科瘤学
  • 手术瘤学手术瘤学
  • 癌症基因组学 癌症基因组学

背景情况:

  • 狂肌肉瘤 (RMS) 是一个重要的儿科癌症,占所有儿科瘤的一半.
  • 局部控制疗法的进步改善了RMS患者的治疗结果,包括转移性疾病患者.
  • 目前的趋势包括更广泛地使用核心针和哨兵节点活检来确定淋巴结的阶段.

研究的目的:

  • 审查了近期拉布多米索尔科马 (RMS) 管理方面的进展.
  • 要突出预后因素的演变和RMS中的风险分层.
  • 讨论北美和欧洲外科瘤学团体在标准化护理方面的持续努力.

主要方法:

  • 审查目前的治疗策略对于rhabdomyosarcoma.
  • 分析不断发展的诊断和分期技术,包括分子标记物.
  • 检查手术瘤学合作小组中的合作努力.

主要成果:

  • 由于加强局部控制和手术切除策略,改善了RMS治疗的结果.
  • 越来越多地采用先进的活检技术来准确的淋巴结分期.
  • 开发精细的预后因素,优先考虑融合状态,而不是组织学风险分层.

结论:

  • 目前的治疗策略已经显著改善了儿科rhabdomyosarcoma的治疗结果.
  • 融合状态对风险分层变得越来越重要,指导个性化治疗.
  • 持续的国际合作对于克服哲学差异和标准化RMS患者的最佳护理至关重要.